摘要
目的应用阿托伐他汀干预实验性变态反应性脑脊髓炎(experiment allergic encephalom yelitis,EAE)大鼠,探讨药物对于疾病发病、炎性细胞浸润及TNF-α和iNOS表达的影响。方法采用豚鼠脊髓匀浆诱导Wistar大鼠建立EAE模型,口服给药干预,观察药物对大鼠发病、炎性细胞浸润情况及TNF-α和iNOS表达的影响。结果阿托伐他汀降低了大鼠发病率(P<0.05),改善了大鼠发病的严重程度(P<0.05),抑制了炎性细胞向脊髓组织的的浸润(P<0.05),降低了脊髓中iNOS的表达(P<0.05),但对于血清中TNF-α的水平没有影响(P>0.05)。结论阿托伐他汀降低了大鼠的发病率,减轻了实验性变态反应性脊髓炎大鼠发病的严重程度及炎性细胞的浸润、iNOS的表达。
Objective To investigate the therapeutic potential of atorvastitim in the treatment of neuroinfiammatory diseases like MS. Methods EAE was induced in Wistar rats by immunization with GPSCH. After oral administration of atorvastatin, the results were analyzed in the incidence of disease,the development of neurological signs, the level of TNF- α in serum, the expression of iNOS in spinal cord. Results Atorvastatin reduced the degree and frequency of EAE attacks （ P 〈 0.05 ） , and nhibited the expression of iNOS and the leukocyte infiltration and inflammation in spinal cord of EAE rats （ P 〈 0.05）. Conclusions Atorvastatin can inhibit the leukocyte infiltration and inflammation and the expression of iNOS, so to ameliorate EAE in rats.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2007年第9期533-536,共4页
Chinese Journal of Nervous and Mental Diseases
基金
河北省卫生厅资助课题(编号:02074)
